Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Technology evaluation: BLP-25, Biomira Inc.

¹Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. m.morse@cgct.duke.edu

Current Opinion in Molecular Therapeutics

|March 16, 2001

Summary

Biomira is developing BLP-25, a MUC-1 peptide-based cancer vaccine targeting common solid tumors. This therapeutic vaccine aims to overcome MUC-1-induced T-cell suppression, potentially enhancing cancer treatment efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial.

ESMO gastrointestinal oncology·2026

Same author

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

Journal for immunotherapy of cancer·2019

Same author

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018

Same author

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

The British journal of dermatology·2018

Same author

X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.

Cell death & disease·2016

Area of Science:

Oncology
Immunology
Vaccine Development

Background:

MUC-1 mucin, overexpressed in over 90% of common solid tumors, suppresses immune responses, including killer T-cell activity, by over 70%.
Biomira is developing BLP-25, a MUC-1 peptide-based vaccine, currently in Phase II trials for non-small cell lung cancer (NSCLC).

Purpose of the Study:

To evaluate the potential of BLP-25, a MUC-1 peptide-based vaccine, for cancer treatment.
To investigate the incorporation of IL-2 into a liposomal delivery system for BLP-25 to enhance immune response.
To assess the potential of therapeutic cancer vaccines targeting MUC-1 through a research collaboration with Axis Genetics.

Main Methods:

Phase II clinical trials for non-small cell lung cancer (NSCLC).
Development of a liposomal delivery system incorporating IL-2 to enhance BLP-25 efficacy.
Preclinical evaluation of Axis Genetics' MUC-1 targeting vaccine.

Main Results:

BLP-25 is designed to elicit an immune response against MUC-1.
IL-2 has been shown to reverse MUC-1-mediated T-cell suppression and enhance cellular immune response over 100-fold.
Biomira is evaluating Axis Genetics' MUC-1 vaccine in preclinical trials.

Conclusions:

BLP-25 shows potential as a therapeutic cancer vaccine by targeting MUC-1.
Combining BLP-25 with IL-2 may significantly enhance anti-tumor immune responses.
Further research and development are ongoing to explore the full potential of MUC-1 peptide-based cancer vaccines.

Related Experiment Videos